Insulet (NASDAQ:PODD) Sets New 52-Week Low – Here’s Why

Insulet Corporation (NASDAQ:PODD)’s stock price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $220.28 and last traded at $226.71, with a volume of 300006 shares traded. The stock had previously closed at $236.07.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Study results support long‑term product thesis: new study outcomes backing a fully closed‑loop insulin pump for type 2 diabetes could reinforce Insulet’s growth runway if commercial adoption follows. Study Outcomes
• Neutral Sentiment: Company says affected supply is limited and replacement capacity exists — Insulet initiated a voluntary medical device correction and communicated it publicly, and management stated they expect to replace impacted Pods without disrupting overall availability. Investors should watch follow‑up disclosures for replacement costs and execution risk. Company Correction
• Negative Sentiment: Recall / Medical device correction highlights manufacturing defect — Regulators and media report specific U.S. lots of Omnipod 5 Pods were recalled/subject to correction because of potential tubing tears that could under‑deliver insulin, increasing short‑term revenue and reputation risk. Reuters Recall
• Negative Sentiment: Safety reports and potential patient harm amplified selling — Insulet disclosed multiple serious adverse event reports (including hospitalizations and DKA tied to under‑delivery) which raises regulatory/legal exposure and hurts investor confidence. Seeking Alpha Recall
• Negative Sentiment: Multiple securities‑fraud investigations and law‑firm notices have been announced — several firms are soliciting claimants alleging the company may have misled investors about the issue, creating potential litigation risk and additional headline pressure. Fraud Investigation
• Negative Sentiment: Market coverage and technicals: the headlines drove the stock to a 52‑week low and broader market writeups (MSN/Benzinga) are amplifying downward momentum. Expect short‑term analyst and sentiment reactions until clarity on scope, costs and regulatory response. 52‑Week Low

Analysts Set New Price Targets

Several equities analysts have weighed in on PODD shares. Citigroup cut their target price on Insulet from $345.00 to $338.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Partners decreased their price target on Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. JPMorgan Chase & Co. lowered their price objective on Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a report on Thursday, February 19th. Canaccord Genuity Group cut their price objective on Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Finally, Evercore set a $340.00 target price on Insulet in a report on Thursday, February 19th. Twenty analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $354.24.

Insulet Trading Down 6.9%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The company’s 50 day moving average is $258.47 and its 200 day moving average is $297.07. The stock has a market capitalization of $15.48 billion, a price-to-earnings ratio of 62.81, a PEG ratio of 1.31 and a beta of 1.42.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the business posted $1.15 EPS. On average, research analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.39% of the stock is owned by corporate insiders.

Institutional Trading of Insulet

A number of hedge funds have recently modified their holdings of PODD. Winnow Wealth LLC bought a new position in Insulet during the third quarter worth about $862,000. Machina Capital S.A.S. acquired a new stake in Insulet during the third quarter valued at approximately $2,778,000. ING Groep NV grew its stake in shares of Insulet by 88.5% in the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after purchasing an additional 8,123 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Insulet by 38.1% in the 3rd quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after buying an additional 12,754 shares in the last quarter. Finally, Jump Financial LLC raised its holdings in shares of Insulet by 12.0% in the 2nd quarter. Jump Financial LLC now owns 66,170 shares of the medical instruments supplier’s stock worth $20,789,000 after buying an additional 7,070 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.